greeksoup/ stock research

Pfizer (PFE) Q4 FY2022 earnings: revenue $24.3 billion, up 2.8% on the year

Pfizer Inc. (PFE) reported revenue of $24.3 billion for Q4 FY2022, the quarter ended 31 December 2022, up 2.8% on the same quarter a year earlier. Net income was $5.0 billion, up 47.2% on the year, and diluted earnings per share $0.87. The figures are the company's own, from the 10-K it filed with the SEC on 23 February 2023.

Revenue
$24.3 billion
+2.8% on the year · +7.3% on the quarter
Q1 FY2021Q4 FY2022
Operating margin
n/a
Q1 FY2021Q4 FY2022
Net income
$5.0 billion
+47.2% on the year · -42.0% on the quarter
Q1 FY2021Q4 FY2022
Diluted EPS
$0.87
+47.5% on the year · -42.4% on the quarter
Q1 FY2021Q4 FY2022

this quarterthe same quarter a year earlierHover a bar for its figure.

Income statement (profit and loss)

$ millionQ4 FY2022Q3 FY2022Q4 FY2021On the quarterOn the yearLast 8 quarters
Revenue24,28922,63823,635+7.3%+2.8%
Cost of revenue9,6496,0639,736+59.1%-0.9%
Gross profit14,64016,57513,899-11.7%+5.3%
Gross margin60.3%73.2%58.8%
Research and development3,6162,6965,909+34.1%-38.8%
Selling, general and administrative4,6453,3914,099+37.0%+13.3%
Interest expense312311314+0.3%-0.6%
Pre-tax income5,2319,0013,843-41.9%+36.1%
Income tax230356249-35.4%-7.6%
Effective tax rate4.4%4.0%6.5%
Net income4,9948,6083,393-42.0%+47.2%
Net margin20.6%38.0%14.4%
Diluted EPS$0.87$1.51$0.59-42.4%+47.5%
$ million except per share.
Read moreFourth quarters are the year less the first three quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed.

Cash flow

$ millionQ4 FY2022Q3 FY2022Q4 FY2021On the quarterOn the yearLast 8 quarters
Operating cash flow8,5825,9745,914+43.7%+45.1%
Capital expenditure1,001841993+19.0%+0.8%
Free cash flow7,5815,1334,921+47.7%+54.1%
Free cash flow margin31.2%22.7%20.8%
Cash from investing-4,410-627-2,586
Cash from financing-5,015-5,761-3,351
Depreciation and amortisationn/a1,183n/a
Share-based compensation364135495+169.6%-26.5%
Buybacks0.00.00.0
Dividends paid2,2452,2452,1890.0%+2.6%
Dividend per sharen/a$0.40n/a
Diluted shares, weighted5,743m5,718m5,708m+0.4%+0.6%
Shares outstanding at period end5,619m5,646m5,619m-0.5%0.0%

Cash flow lines for the quarter; where the company files them year to date, the quarter is the difference between two filings.

Balance sheet

$ millionQ4 FY2022Q3 FY2022Q4 FY2021On the quarterOn the yearLast 8 quarters
Shareholders' equity95,66192,63177,201+3.3%+23.9%
Non-controlling interest256259262-1.2%-2.3%
Debt35,82936,66938,436-2.3%-6.8%
Operating lease liabilities2,597n/a2,510+3.5%
Other liabilities62,86265,79163,067-4.5%-0.3%
Total liabilities and equity197,205195,350181,476+0.9%+8.7%
Fixed assets16,27415,44114,882+5.4%+9.4%
Goodwill51,37549,44149,208+3.9%+4.4%
Intangible assets43,37028,15125,146+54.1%+72.5%
Investments33,81234,06443,540-0.7%-22.3%
Cash and equivalents4161,2981,944-68.0%-78.6%
Receivables10,95216,07611,479-31.9%-4.6%
Inventory8,9819,5139,059-5.6%-0.9%
Other assets32,02541,36626,218-22.6%+22.1%
Total assets197,205195,350181,476+0.9%+8.7%

Questions

What was Pfizer's revenue in Q4 FY2022?

Pfizer (PFE) reported revenue of $24.3 billion for Q4 FY2022, the quarter ended 31 December 2022, up 2.8% on the same quarter a year earlier.

How much did Pfizer earn in Q4 FY2022?

Net income for Q4 FY2022 was $5.0 billion, up 47.2% on the year, and diluted earnings per share $0.87.

When did Pfizer report Q4 FY2022 results?

Pfizer filed its 10-K for the year that ended with the quarter on 23 February 2023; the fourth quarter is the year less the first three.

Quarterly results, the last 20 quarters

Q4 FY2021 * †Q1 FY2022Q2 FY2022Q3 FY2022Q4 FY2022 *Q1 FY2023 †Q2 FY2023 †Q3 FY2023 †Q4 FY2023 *Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024 *Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025 *Q1 FY2026Q2 FY2026Q3 FY2026
Revenue23,63525,66127,74222,63824,28918,48613,00713,49114,24814,87913,28317,70217,76313,71514,65316,65417,55714,45115,03416,583
Cost of revenue9,7369,9848,6486,0639,6494,8863,2379,2697,5623,3793,3005,2635,9092,8453,7784,1725,2723,5484,0924,028
Gross profit13,89915,67719,09416,57514,64013,6009,7704,2226,68611,5009,98312,43911,85410,87010,87512,48212,28510,90310,94212,555
Gross margin59%61%69%73%60%74%75%31%47%77%75%70%67%79%74%75%70%75%73%76%
R&D5,9092,3012,8152,6963,6162,5052,6482,7112,8152,4932,6962,5983,0352,2032,4822,5463,2062,4902,8093,016
SG&A4,0992,5933,0483,3914,6453,4183,4973,2814,5753,4953,7173,2444,2743,0313,4153,1864,1622,9613,4113,279
Interest expense314322293311312318508695688790778783740654654652711668667662
Pre-tax income3,8439,05011,4479,0015,2316,2702,269-3,352-4,1293,421-1034,715-10.02,7853,0443,334-1,6433,170-6533,385
Tax rate6%13%14%4%4%11%-3%n/an/a9%n/a5%n/a-7%5%-6%n/a15%n/a4%
Net income3,3937,8649,9068,6084,9945,5432,327-2,382-3,3693,11541.04,4654102,9672,9103,541-1,6472,687-2483,242
Net margin14%31%36%38%21%30%18%-18%-24%21%0%25%2%22%20%21%-9%19%-2%20%
Diluted EPS$0.59$1.37$1.73$1.51$0.87$0.97$0.41-$0.42-$0.60$0.55$0.01$0.78$0.07$0.52$0.51$0.62-$0.29$0.47-$0.04$0.56
Operating cash flow5,9146,5418,1705,9748,5821,212-1,2083,4565,2401,090-1,7816,7146,7212,335-5824,6035,3482,6158355,375
Capital expenditure9936437518411,0011,1399148101,044704637651917564618602845436533573
Free cash flow4,9215,8987,4195,1337,58173.0-2,1222,6464,196386-2,4186,0635,8041,771-1,2004,0014,5032,1793024,802
Buybacks0.02,0000.00.00.00.00.00.00.0n/an/an/an/an/an/an/an/an/an/an/a
Dividends paid2,1892,2492,2442,2452,2452,3032,3152,3142,3152,3722,3802,3802,3802,4372,4452,4442,4452,4452,4512,451
Shares outstanding5,619m5,645m5,646m5,646m5,619m5,645m5,646m5,646m5,647m5,667m5,667m5,667m5,667m5,685m5,686m5,686m5,686m5,699m5,700m5,700m
Filing10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q10-K10-Q10-Q10-Q
Each quarter as filed, linked to its filing.
Read more* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. A fourth quarter's EPS, and its diluted share count where shown, are from the company's results press release for that quarter, checked against the company's filed figures or a second data source. A quarter marked † is shown as the company last restated it in a later filing, so it compares with the quarters around it on one basis; rest on a figure for the one first filed. EPS is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

10-K for the period ended 31 December 2022, filed 23 February 2023: the filing.